lowest tolerated dose Phase Step 2 Weeks Weeks 5-8 Cagrilintide Dose 0.5 mg/week Purpose Dose escalation Phase Step 3 Weeks Weeks 9-12 Cagrilintide Dose 1.0 mg/week Purpose GI side effects often peak here Phase Step 4 Weeks Weeks 13-16 Cagrilintide Dose 1.7 mg/week Purpose Approaching maintenance Phase Maintenance Weeks Weeks 17+ Cagrilintide Dose 2.4 mg/week Purpose Target dose used in late-stage study protocols Each step lasts 4 weeks
But I think I'd always want to be a functional MRI person because that's going to be very cool as we go forward
Because CJC-1295 is administered subcutaneously in research settings, mild redness, itching, swelling, or bruising at the site is common
Outcome measures for each phase were: (i) the number of trials to criterion, (ii) the reaction time (RT: time (sec) to reach the end of any arm), and (iii) RT variability (RTv: the standard deviation of the differences in RTs between each pair of successive trials, per mouse
Further demonstrating the therapeutic potential of targeting glycolysis, the natural compound derivative D5, sourced from Radix Aucklandiae, attenuates colitis in mice by impeding the nuclear translocation of PKM2 dimers, thereby suppressing glycolytic flux and Th17 cell differentiation (211)
